Is semaglutide legal in Australia?

The short answer

Yes. Semaglutide is a legal substance in Australia, but it is tightly regulated. It is listed on the Australian Register of Therapeutic Goods (ARTG) and is classified as a Schedule 4 (Prescription Only Medicine) under the Poisons Standard. This means approved semaglutide products can only be supplied lawfully as medicines through a prescription from a registered health practitioner and a pharmacy.

Separately, semaglutide is also handled as a reference material within laboratory and research settings. Suppliers such as NovaPeptides supply semaglutide strictly for laboratory research use only, which is a distinct category from an approved medicine supplied for human therapeutic use. The rest of this guide explains how those two things differ.

How the TGA and Poisons Standard classify semaglutide

In Australia, the scheduling of medicines and poisons is set out in the Poisons Standard, also known as the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). The Therapeutic Goods Administration (TGA) is the national regulator responsible for therapeutic goods, including prescription medicines.

Semaglutide sits in Schedule 4 of the Poisons Standard. Schedule 4 is the category for Prescription Only Medicines. Substances are placed in Schedule 4 when their use or supply should be by, or on the order of, persons permitted by State or Territory legislation to prescribe, and when they are available from a pharmacist on prescription.

What Schedule 4 generally means in practice

• A valid prescription from an authorised prescriber is required for lawful supply as a medicine.
• The medicine is dispensed through a pharmacy.
• It is not available for general retail sale over the counter.
• Importation, advertising and supply are subject to therapeutic goods law.

Because semaglutide is Schedule 4, the lawful pathway to obtain it as a medicine is through the regulated prescription and pharmacy system, not through general consumer sale.

Semaglutide is on the ARTG, and which brands are approved

This is where semaglutide differs from some other research peptides. Unlike BPC-157, which has no approved human product in Australia, semaglutide IS the active ingredient in several TGA approved medicines registered on the ARTG. The ARTG is the public register of therapeutic goods that may be lawfully supplied in Australia.

According to publicly available TGA records, approved semaglutide products registered on the ARTG include the following, all sponsored by Novo Nordisk Pharmaceuticals Pty Ltd:

Registered semaglutide products (sponsor: Novo Nordisk)

• Ozempic, a solution for injection in a pre-filled pen, first entered on the ARTG in 2019.
• Wegovy, a solution for injection, entered on the ARTG in 2022.
• Rybelsus, an oral tablet form of semaglutide, entered on the ARTG in 2022.

The existence of these registered products means semaglutide has passed TGA assessment for quality, safety and efficacy for its approved uses. These are genuine medicines with Product Information documents, and they are the only lawful route to using semaglutide therapeutically in Australia.

Approved medicine versus research-grade supply

The single most important distinction in this topic is the difference between an approved medicine and research-grade material. They are not the same thing and are not governed by the same rules.

An approved medicine, such as Ozempic, Wegovy or Rybelsus, is a finished product that has been registered on the ARTG for human therapeutic use. It is manufactured to pharmaceutical standards, carries approved labelling and Product Information, and is supplied on prescription for its approved indications.

Research-grade semaglutide, by contrast, is a laboratory reference material supplied for in vitro and laboratory research use only. It is not a registered medicine, it is not supplied for human therapeutic use, and it is not intended for administration to people or animals. NovaPeptides supplies semaglutide on this research-use-only basis.

Research-grade material is for laboratory investigation only. It is never a substitute for an approved medicine prescribed and dispensed through the regulated healthcare system.

What research use only actually means

Research use only (RUO) is a supply category used for substances intended for laboratory and scientific investigation rather than human or veterinary therapeutic use. The label is not a marketing phrase. It defines the lawful scope of how the material may be supplied and used.

Core features of research-use-only supply

• Intended for in vitro and laboratory research only.
• Not for human or animal consumption or administration.
• Not presented, labelled or supplied as a medicine or therapeutic good.
• No therapeutic, efficacy, weight-management or clinical claims are made about it.

NovaPeptides does not provide dosing information, human protocols or any therapeutic guidance for research materials, and nothing in this article should be read as such. The research-use-only framing exists precisely because these materials are outside the approved-medicine pathway.

How to verify research-grade material responsibly

When sourcing any research material, independent verification of identity and purity matters. For laboratory work, the quality of the reference material directly affects the reliability of any results.

What to look for in a research supplier

• A Certificate of Analysis (CoA) for the specific batch.
• Third-party or independent analytical testing, rather than supplier claims alone.
• Clear research-use-only labelling and documentation.
• Transparent batch identifiers so a result can be traced to a specific lot.

NovaPeptides supports batch-level verification through third-party testing, including independent analysis via Novagen, so a stated result can be tied back to a specific batch. This is about transparency of the material itself for research purposes, not about any human use.

Sport and anti-doping status

Athletes who are subject to anti-doping rules should not assume a substance is permitted simply because it is a registered medicine. Anti-doping status is governed by the World Anti-Doping Agency (WADA) Prohibited List, which Sport Integrity Australia administers domestically, and the list is reviewed and updated each year.

The status of any specific substance in sport can change between annual lists and can differ in-competition versus out-of-competition. Because of this, athletes should always check the current WADA Prohibited List and Sport Integrity Australia resources, and use the official Check Your Substances tool, rather than relying on general articles. This guide does not state a sport classification for semaglutide and defers to the current official sources.

Summary

Semaglutide is legal in Australia as a tightly regulated substance. It is registered on the ARTG as an approved prescription medicine in products such as Ozempic, Wegovy and Rybelsus, all sponsored by Novo Nordisk, and it is classified Schedule 4, Prescription Only Medicine, under the Poisons Standard. The lawful route to semaglutide as a medicine is a prescription dispensed through a pharmacy.

Separately, semaglutide can be supplied as a research-grade reference material for laboratory research use only, which is a distinct category from an approved medicine and is never intended for human use. NovaPeptides supplies semaglutide strictly on that research-use-only basis. Anyone considering semaglutide therapeutically should speak with a qualified health practitioner and rely on the current TGA position.

Frequently asked questions